E
Erminio Bonizzoni
Researcher at University of Milan
Publications - 111
Citations - 11281
Erminio Bonizzoni is an academic researcher from University of Milan. The author has contributed to research in topics: Palonosetron & Stent. The author has an hindex of 39, co-authored 105 publications receiving 10459 citations. Previous affiliations of Erminio Bonizzoni include Vita-Salute San Raffaele University.
Papers
More filters
Journal ArticleDOI
Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.
Ioannis Iakovou,Thomas Schmidt,Erminio Bonizzoni,Lei Ge,Giuseppe Sangiorgi,Goran Stankovic,Flavio Airoldi,Alaide Chieffo,Matteo Montorfano,Mauro Carlino,Iassen Michev,Nicola Corvaja,Carlo Briguori,Ulrich Gerckens,Eberhard Grube,Antonio Colombo +15 more
TL;DR: The cumulative incidence of stent thrombosis 9 months after successful drug-eluting stent implantation in consecutive "real-world" patients was substantially higher than the rate reported in clinical trials.
Journal ArticleDOI
A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project.
Giancarlo Agnelli,Giorgio Bolis,Lorenzo Capussotti,Roberto Mario Scarpa,Francesco Tonelli,Erminio Bonizzoni,Marco Moia,Fabio Parazzini,Romina Rossi,Francesco Sonaglia,Bettina Valarani,Carlo Bianchini,Gualberto Gussoni +12 more
TL;DR: In patients undergoing cancer surgery, VTE is the most common cause of death at 30 days after surgery, and a remarkable proportion of events occurring late after surgery is found.
Journal ArticleDOI
Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry.
Torbjörn Tomson,Dina Battino,Erminio Bonizzoni,John Craig,Dick Lindhout,Anne Sabers,Emilio Perucca,Frank J.E. Vajda +7 more
TL;DR: The risk of major congenital malformations is influenced not only by type of antiepileptic drug, but also by dose and other variables, which should be taken into account in the management of epilepsy in women of childbearing potential.
Journal ArticleDOI
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study
Giancarlo Agnelli,Gualberto Gussoni,Carlo Bianchini,Melina Verso,Mario Mandalà,Luigi Cavanna,Sandro Barni,Roberto Labianca,Franco Buzzi,Giovanni Scambia,Rodolfo Passalacqua,Sergio Ricci,Giampietro Gasparini,Vito Lorusso,Erminio Bonizzoni,Maurizio Tonato +15 more
TL;DR: Nadroparin reduces the incidence of thromboembolic events in ambulatory patients with metastatic or locally advanced cancer who are receiving chemotherapy, and future studies should focus on patients who are at a high risk for thrombolic events.
Journal ArticleDOI
Incidence and Predictors of Drug-Eluting Stent Thrombosis During and After Discontinuation of Thienopyridine Treatment
Flavio Airoldi,Antonio Colombo,Nuccia Morici,Azeem Latib,John Cosgrave,Lutz Buellesfeld,Erminio Bonizzoni,Mauro Carlino,Ulrich Gerckens,Cosmo Godino,Gloria Melzi,Iassen Michev,Matteo Montorfano,Giuseppe Sangiorgi,Asif Qasim,Alaide Chieffo,Carlo Briguori,Eberhard Grube +17 more
TL;DR: Discontinuation of thienopyridine therapy was the major determinant of ST within the first 6 months, but insufficient information is available to determine whether there is benefit in continuing a thienobyridine beyond 6 months.